VERACYTE, INC. (VCYT) Stock
3 members of Congress disclosed 14 trades in VCYT since 2019: 8 purchases and 6 sales, most recently Gilbert Cisneros (purchase, Mar 3, 2026). 6 of the hedge funds AlphaScala tracks reported VCYT in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is ARK Invest's at $134.84M. Company insiders reported 0 open-market buys and 13 sales on SEC Form 4 in the 90 days to Nov 3, 2026.
Which members of Congress traded VERACYTE, INC. (VCYT)?
Most recent: Gilbert Cisneros (purchase, Mar 3, 2026); records start Dec 6, 2019.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-03-03 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-02-18 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-11-12 | partial sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-06-16 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2023-10-16 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2023-09-15 | partial sale | $1k – $15k |
| Dan Goldman D-NY · House | 2023-04-10 | partial sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2020-12-23 | partial sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 2, 2026.
See all VCYT political trades →Which hedge funds own VCYT?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| ARK Invest Cathie Wood | 2.30M | $134.84M | -25% |
| Point72 Steve Cohen | 738K | $43.33M | +52% |
| D.E. Shaw David Shaw | 413K | $24.26M | +880% |
| Millennium Management Israel Englander | 72K | $4.23M | NEW |
| Bridgewater Associates Ray Dalio | 58K | $3.42M | -36% |
| Marshall Wace | 6K | $373.9K | -79% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are VERACYTE, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 27, 26 | Eastham Karin | Director | SELL | 14.8K | $743K |
| Oct 27, 26 | Holstein Jens | Director | SELL | 7.5K | $375K |
| Oct 19, 26 | Bhanji Muna | Director | SELL | 1.9K | $81K |
| Sep 24, 26 | Holstein Jens | Director | SELL | 7.5K | $353K |
| Sep 21, 26 | Leite John | Global Chief Commercial Off | SELL | 4.0K | $161K |
| Sep 14, 26 | Holstein Jens | Director | SELL | 5.0K | $205K |
| Sep 4, 26 | Febbo Phillip G. | Chief Scientific & Med Officer | SELL | 10.4K | $446K |
| Sep 4, 26 | Febbo Phillip G. | Chief Scientific & Med Officer | SELL | 2.7K | $118K |
| Sep 4, 26 | Chambers Rebecca | Chief Financial Officer | SELL | 2.5K | $106K |
| Sep 4, 26 | Chambers Rebecca | Chief Financial Officer | SELL | 1.2K | $51K |
SEC Form 4 filings as of Nov 3, 2026
See cluster-buy signals across all tickers →VCYT price chart
Powered by TradingViewWhat does VERACYTE, INC. do?
Veracyte Inc. is a global diagnostics company specializing in advanced genomic tests that provide clinicians with precise insights to diagnose and treat cancer. Its portfolio features key products such as Afirma for thyroid cancer, Decipher Prostate and Decipher Bladder for prostate and bladder cancers respectively, Prosigna for breast cancer, Envisia for interstitial lung diseases including idiopathic pulmonary fibrosis, and Percepta for lung cancer diagnosis. These molecular diagnostics leverage genomic sequencing, machine learning, and clinical data through the company's innovative Veracyte Diagnostics Platform, enabling AI-assisted analysis and evidence generation to support personalized treatment decisions and avoid unnecessary surgeries. Veracyte Inc. operates centralized CLIA labs in the US and offers distributed in vitro diagnostics for international markets across North America, Europe, and the Middle East, serving healthcare providers, biopharmaceutical partners, and biotechnology sectors. Founded in 2006 and headquartered in South San Francisco, California, the company plays a vital role in precision oncology by transforming cancer care with actionable genomic information at critical decision points.